Abstract: Micronized tanaproget, purified tanaproget Form I, and micronized, purified tanaproget Form I are provided. Also provided are compositions containing one or more of the prepared tanaproget forms, methods of using one or more of the prepared tanaproget forms, and kits containing one or more of the prepared tanaproget forms.

Abstract: The present invention provides compounds and compositions, methods of making them, and methods of using them to modulate ?7 nicotinic acetylcholine receptors and/or to treat any of a variety of disorders, diseases, and conditions. Provided compounds can affect, among other things, neurological, psychiatric and/or inflammatory system.

Abstract: This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents.

Abstract: Methods for preparing compound of formula (I) are described, wherein R1-R3 are defined herein, as are methods for preparing the intermediates formed therein. Also described are methods for enantioselectively preparing a chiral compound of the following structure, wherein R2 and R3 are defined herein.

Abstract: A novel trifluoroacetylating agent, i.e., N-trifluoroacetylmorpholine, is described. This reagent is useful in the preparation of phenyl and heterocyclic sulfonamide compounds. Methods are therefore described for preparing sulfonamide compounds of the following structure, wherein R1 and R2 are defined herein, using N-trifluoroacetylmorpholine. The sulfonamide compounds that may be prepared as described herein include 5-chloro-thiophene-2-sulfonic acid [(1S,2R)-2-(3,5-difluoro-phenyl)-3,3,3-trifluoro-1-hydroxymethyl-propyl]-amide using N-trifluoroacetylmorpholine.

Abstract: The present invention provides processes for the preparation of compounds of Formula I, which are useful in the preparation of pharmaceuticals for the treatment of inflammatory diseases. The compounds of Formula I are also useful as pharmaceuticals.

Abstract: The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1 (PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.

Abstract: The present invention provides improved synthetic methods for the preparation of compounds that modulate proliferation or differentiation in a cell or tissue.

Abstract: Processes for dialkylating indolinones, specifically indolin-2-ones are provided. The processes for dialkylating an indolin-2-one include performing the dialkylation in the presence of at least 2 equivalents of a first base, a second base containing at least 1 equivalent of lithium diisopropylamide, and an alkylating agent. Processes for preparing a compound of the structure are provided, wherein R1, R3, R4, R6, R7, R9, and R10 are as defined herein. In one embodiment, a process for preparing 5-(4?-fluoro-2?-oxospiro[cyclopropane-1,3?-indoline]-5?-yl)-1-methyl-1H-pyrrole-2-carbonitrile is provided.

Abstract: Processes are disclosed for preparing substituted aryl cycloalkanol derivatives, particularly chiral substituted aryl cycloalkanol derivatives of the general formula:

Abstract: Micronized tanaproget, purified tanaproget Form I, and micronized, purified tanaproget Form I are provided. Also provided are compositions containing one or more of the prepared tanaproget forms, methods of using one or more of the prepared tanaproget forms, and kits containing one or more of the prepared tanaproget forms.

Abstract: The present invention provides processes for the preparation of substituted naphthylindole derivatives that can be used as inhibitors of plasminogen activator inhibitor-1(PAI-1). In certain embodiments of the invention, the processes involve reactions that include one or more of an Oppenauer oxidation, a Fischer indole synthesis, a methyl ether cleavage, or coupling a substituted methyltetrazole with a substituted naphthol.

Abstract: The present invention concerns production of a compound of the formula or a pharmaceutically acceptable salt thereof by a process which utilizes the cyclization of a compound of the formula: where Ar, Y, R1, Ry, R2, and m are as defined herein.

Abstract: This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents.

Abstract: The present invention relates to methods of making Gonadotropin Releasing Hormone (“GnRH”) (also known as Leutinizing Hormone Releasing Hormone) receptor antagonists.

Abstract: The present invention provides processes for the preparation of compounds of Formula III that are useful in the preparation of pharmaceuticals for the treatment of inflammatory diseases.

Abstract: The present invention provides processes for the preparation of compounds of Formula I, which are useful in the preparation of pharmaceuticals for the treatment of inflammatory diseases. The compounds of Formula I are also useful as pharmaceuticals.

Abstract: This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents.

Abstract: The present invention provides a new process and intermediates for the production of antiviral compound 4?,4-bis-{4,6-bis-[3-(bis-carbamoyl-methyl-1-sulfamoyl)-phenylamino]-[1,3,5]triazin-2-ylamino}-biphenyl-2,2?-disulfonic acid and its pharmaceutically acceptable salts.

Abstract: This invention relates to a process for the preparation of 6-hydroxyequilenins, which are useful as estrogenic agents.